We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Alternate Gene May Help in Muscular Dystrophy

By Biotechdaily staff writers
Posted on 09 Jun 2002
The utrophin gene, if overexpressed, may be able to substitute for the missing dystrophin gene and at least partially alleviate the symptoms of Duchenne's muscular dystrophy (DMD). More...
Duchenne's muscular dystrophy is one of the most frequent hereditary diseases of men, affecting one in 3,500 boys. It occurs when the dystrophin gene, located on the short arm of the X chromosome, is nonfunctional. Without the dystrophin protein, muscle tissues cannot tolerate the stress of contraction and relaxation sufficiently and eventually break down.

As an alternative to gene therapy to replace the missing dystrophin, scientists have been investigating the utrophin gene. This gene is found in several types of tissue, and its protein product functions similarly to dystrophin protein. However, the utrophin protein does not function as well as the dsytrophin protein, nor is it present in as high a concentration.

In a report in the May 15, 2002, issue of the Journal of Neurological Sciences, researchers at the University of Pennsylvania School of Medicine (Philadelphia, USA) detail the cellular mechanisms that promote and regulate the transcription of the utrophin gene into protein. Their findings may help to design drugs that will produce excess utrophin in people suffering from DMD and help to compensate for the missing dystrophin protein.

"Utrophin has been a major focus in muscular dystrophy. Dystrophin and utrophin perform similar tasks at the neuromuscular junction – where nerve cells meet muscle tissue – and studies have shown that utrophin over-production reverses the symptoms of muscular dystrophy in mice,” said Dr. Tejvir S. Khurana. "Over-production of utrophin may be a viable alternative to adding a working copy of the dystrophin gene through gene therapy,” said Dr. Khurana. "The available research supports the idea that if you can crank up the production of utrophin, you will compensate for the lack of dystrophin.”

The mechanism for transcriptional regulation of utrophin is quite complex and not yet completely understood, but the researchers did demonstrate promotion of utrophin in response to heregulin and transcription factor Sp1. This work was carried out in Drosophila S2 cells.
"These findings will help define targets for stimulating the muscle cells' native mechanisms into producing more utrophin,” added Dr. Khurana. "And while a substitute isn't always as good as the original, in this case good enough may well result in a substantial improvement.”



Related Links:
University of Pennsylvania School of Medicine

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.